Good news! We’ve made it easier for Texas Children’s Health Plan members to log in to the MyChart website. Now, you can access all your MyChart health care features anytime, anywhere using our new sign-in widget. Click the link to log in now
¡Buenas noticias! Hemos hecho más fácil el inicio de sesión en MyChart para nuestros miembros de Texas Children’s Health Plan. Ahora puedes acceder a todas las funciones de cuidado médico de MyChart en cualquier momento y desde cualquier lugar mediante nuestro nuevo widget de inicio de sesión. Haz clic en el enlace para iniciar sesión.
Important UpdateActualización importante:
Good news! All CHIP, STAR, and STAR Kids Member Handbooks are now available online. Quick, easy access to your benefits and coverage information - any time!
¡Buenas noticias! Todos los manuales para miembros de CHIP, STAR y STAR Kids ya están disponibles en línea. Obtén acceso rápido y sencillo a la información sobre tus beneficios y cobertura, ¡en cualquier momento!
Change in Preferred Drug List Status for Antivirals, Topical Drug Class
Date: December 23, 2025
Attention: Providers
Effective date: December 29,2025
Call to action:Effective December 29, 2025, the Texas Health and Human Services (HHS) removed non-preferred status from certain acyclovir products on the preferred drug list. This update was implemented in response to Bausch Health, the manufacturer of Zovirax® cream and ointment, exiting the Texas Medicaid Drug Rebate Program, and is intended to maintain access to acyclovir topical therapy without requiring preferred drug list prior authorization.
Impacted Medication
Type of Change
Effective Date
ACYCLOVIR 5% OINTMENT [G]
Generic now preferred
12/29/2025
ACYCLOVIR 5% CREAM [G]
Generic now preferred
12/29/2025
[G] Signals the medication is generic.
How this impacts providers: The change will allow providers to prescribe the above drugs in the table without requiring PDL prior authorization at this time and continue accessing necessary medication for their patients.
Next step for Providers: Prescribers are encouraged to proactively obtain a prescription for the preferred alternatives to avoid disruption in patient’s therapy. Prescribers should share this communication with their staff.
